Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse
Status:
Active, not recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
Assessing the safety and efficacy of the bevacizumab (FKB238), Olaparib and Durvalumab (MEDI
4736) combination in patient with high grade serous or high grade endometrioid or other high
grade epithelial non mucinous ovarian tumor, with at least one previous line of
platinum-taxane chemotherapy, and present with platinum resistant disease (PRR) or
platinum-sensitive relapse (PSR), whatever the line of chemotherapy given at relapse.